CHILL NOT KILL
LIVE

Serial Number

99420419

Owner

Quell Therapeutics Limited

Attorney

Dmitriy Makarov

Filing Date

Sep 30, 2025

Add to watchlist:

No watchlists yet
View on USPTO

CHILL NOT KILL Trademark

Serial Number: 99420419

CHILL NOT KILL is a trademark filed by Quell Therapeutics Limited on September 30, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). The application is currently pending registration.

Owner Contact Info

Quell Therapeutics Limited (4 trademarks)

3rd Floor, Translation & Innovation Hub
London W120BZ , GB

Entity Type: 99

Trademark Details

Filing Date

September 30, 2025

Registration Date

Not Registered

Goods & Services

Chemical and biological preparations for use in science and industry, other than for medical or veterinary use; chemical and biological preparations for non-medical and non-veterinary purposes, namely, for scientific purposes; chemical and biological preparations for genetically modifying human and animal cells other than for medical or veterinary purposes; chemical and biological reagents for use in the genetic modification of human and animal cells other than for medical or veterinary purposes; human and animal cells and parts thereof, namely, cell receptors, cell surface markers, and transcription factors for scientific and research purposes; T cells for scientific and research purposes; regulatory T cells for scientific and research purposes; biological tissue, namely, blood and cells extracted from humans and animals for scientific and research purposes; immunological agents and preparations in the nature of transduced human and animal cells, for non-medical purposes; biological preparations in the nature of chimeric antigen receptors and preparations thereof for scientific and research purposes other than for medical or veterinary purposes; antibody reagents used for the detection of antigens in cells and tissue and for the proliferation and homing of cells for use in science and industry, other than for medical or veterinary purposes; nucleic acids for scientific purposes; nucleic recombinant acids for scientific purposes; biological preparations in the nature of synthetic deoxyribonucleic acids for use in science and industry, other than for medical or veterinary use; viral vectors for research purposes for use in science and industry; viral and non-viral nucleic acid vectors for research purposes for use in science and industry

Biomanufacturing services for others in the field of pharmaceuticals, namely, biomanufacturing and processing services for others in the field of pharmaceuticals; biomanufacturing services for others in the field of pharmaceuticals, namely, biological, biotechnological and biopharmaceutical manufacturing and processing for others; biological tissue, blood, cell and genetic material processing; biomanufacturing services for others in the field of pharmaceuticals, namely, viral vector production and manufacture; biomanufacturing services for others in the field of pharmaceuticals, namely, gene therapy production and manufacture; custom manufacture of pharmaceutical and biological formulations and products; processing and modification of human and animal cells in the custom manufacture of pharmaceutical and biological formulations and products

Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use for the treatment and prevention of immune-mediated diseases; pharmaceutical, medical and veterinary preparations for diagnostic, therapeutic and prophylactic purposes for the treatment and prevention of immune-mediated diseases; pharmaceutical preparations for cell therapy for the treatment and prevention of immune-mediated diseases; pharmaceutical preparations for gene therapy for the treatment and prevention of immune-mediated diseases; pharmaceutical preparations for genetically modifying human and animal cells for diagnostic and medical purposes for the treatment and prevention of immune-mediated diseases; living human and animal cells for medical and veterinary purposes; living T cells for medical and veterinary purposes; living regulatory T cells for medical and veterinary purposes; blood and living cells extracted from humans and animals which have been adapted for therapeutic medical purposes; pharmaceutical, medical and clinical preparations for use in treatment, amelioration and prophylaxis of diseases, disorders and suppression of the immune system for the treatment and prevention of immune-mediated diseases; pharmaceutical immunological agents and preparations affecting the immune system for medical purposes; pharmaceutical preparations for therapies to modulate the immune system; pharmaceutical preparations for therapies for autoimmune conditions and immunological disorders; biological preparations in the nature of chimeric antigen receptors and therapeutic preparations thereof for the treatment and prevention of immune-mediated diseases; antibodies for medical purposes; pharmaceutical preparations for therapeutic delivery of nucleic acids for the treatment and prevention of immune-mediated diseases; pharmaceutical preparations in the nature of viral vectors for therapeutic and prophylactic purposes for the treatment and prevention of immune-mediated diseases; biological preparations in the nature of nucleic acid vectors for therapeutic and prophylactic purposes for the treatment and prevention of immune-mediated diseases; medical preparations containing viral vectors for therapeutic and prophylactic purposes for the treatment and prevention of immune-mediated diseases; medical preparations containing nucleic acid vectors for therapeutic and prophylactic purposes for the treatment and prevention of immune-mediated diseases

Filing History

TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 3, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 3, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 3, 2026 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Apr 30, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Apr 30, 2026 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 5, 2026 GNRN
NON-FINAL ACTION E-MAILED
Feb 5, 2026 GNRT
NON-FINAL ACTION WRITTEN
Feb 5, 2026 CNRT
ASSIGNED TO EXAMINER
Feb 4, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 30, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 30, 2025 NWOS
NEW APPLICATION ENTERED
Sep 30, 2025 NWAP